Naviter Wealth LLC Has $723,000 Position in Takeda Pharmaceutical Co. $TAK

Key Points

• Naviter Wealth LLC significantly increased its stake in Takeda Pharmaceutical Co. by 327.7%, now holding 46,560 shares valued at $723,000 as of its latest SEC filing.
• Takeda reported $0.52 EPS for the last quarter, surpassing expectations of $0.47, despite a revenue shortfall of $7.45 billion against expectations of $7.96 billion.
• The stock has seen a recent rating downgrade from Zacks Research, shifting from a “hold” to a “strong sell” rating, while the average analyst rating remains a “hold.”

Naviter Wealth LLC raised its stake in shares of Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) by 327.7% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 46,560 shares of the company's stock after buying an additional 35,673 shares during the period. Naviter Wealth LLC's holdings in Takeda Pharmaceutical were worth $723,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. FNY Investment Advisers LLC acquired a new stake in shares of Takeda Pharmaceutical during the 1st quarter valued at $37,000. Farther Finance Advisors LLC raised its holdings in shares of Takeda Pharmaceutical by 29.2% during the 1st quarter. Farther Finance Advisors LLC now owns 4,620 shares of the company's stock valued at $69,000 after purchasing an additional 1,045 shares in the last quarter. Fifth Third Bancorp raised its holdings in shares of Takeda Pharmaceutical by 85.5% during the 1st quarter. Fifth Third Bancorp now owns 5,232 shares of the company's stock valued at $78,000 after purchasing an additional 2,411 shares in the last quarter. GAMMA Investing LLC raised its holdings in shares of Takeda Pharmaceutical by 22.6% during the 1st quarter. GAMMA Investing LLC now owns 7,042 shares of the company's stock valued at $105,000 after purchasing an additional 1,296 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd bought a new position in shares of Takeda Pharmaceutical during the 1st quarter valued at $125,000. Institutional investors and hedge funds own 9.17% of the company's stock.

Takeda Pharmaceutical Stock Performance

Shares of TAK opened at $13.80 on Wednesday. The company has a market capitalization of $43.90 billion, a PE ratio of 45.98 and a beta of 0.21. Takeda Pharmaceutical Co. has a one year low of $12.80 and a one year high of $15.69. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.16 and a quick ratio of 0.59. The company's fifty day moving average price is $14.84 and its 200 day moving average price is $14.77.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last announced its earnings results on Wednesday, July 30th. The company reported $0.52 EPS for the quarter, topping the consensus estimate of $0.47 by $0.05. The firm had revenue of $7.45 billion for the quarter, compared to the consensus estimate of $7.96 billion. Takeda Pharmaceutical had a net margin of 3.20% and a return on equity of 10.50%. Takeda Pharmaceutical has set its FY 2025 guidance at 3.360-3.360 EPS. As a group, analysts expect that Takeda Pharmaceutical Co. will post 1.64 earnings per share for the current year.

Analyst Ratings Changes

TAK has been the topic of a number of recent research reports. Zacks Research downgraded shares of Takeda Pharmaceutical from a "hold" rating to a "strong sell" rating in a report on Thursday, August 21st. Weiss Ratings restated a "hold (c+)" rating on shares of Takeda Pharmaceutical in a report on Tuesday. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold".

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.

Want to see what other hedge funds are holding TAK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Takeda Pharmaceutical Co. (NYSE:TAK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.